ALPHARETTA, Ga., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...
CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently approved as an oral tablet ...
Clearside’s patented, proprietary suprachoroidal space (SCS ®) injection treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The Company ...
Hi, my name is Rahul Khurana and I presented some very exciting work at our most recent American Society of Retina Specialists meeting back in Seattle. Tyrosine kinase inhibitors are an exciting new ...
ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
Please provide your email address to receive an email when new articles are posted on . A panel of experts published guidelines on suprachoroidal space injection. The guidelines promote current best ...
Please provide your email address to receive an email when new articles are posted on . PARK CITY, Utah — Suprachoroidal drug delivery for uveitic macular edema provides durable effects in real-world ...
ALPHARETTA, Ga., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
ALPHARETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
ALPHARETTA, Ga., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...